Method Article

Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry

DOI:

10.3791/59755

⸱

July 13th, 2019

In This Article

Summary

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

In this manuscript, a protocol is presented to perform FACS-based measurement of BK-polyomavirus transcriptional activity by using HEK293T cells transfected with a bidirectional reporter plasmid expressing tdTomato and eGFP. This method further allows to quantitatively determine the influence of novel compounds on viral transcription.

Abstract

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Polyomaviruses, like the BK-polyomavirus (BKPyV), can cause severe pathologies in immunocompromised patients. However, since highly effective antivirals are currently not available, methods measuring the impact of potential antiviral agents are required. Here, a dual fluorescence reporter that allows the analysis of the BKPyV non-coding control-region (NCCR) driven early and late promoter activity was constructed to quantify the impact of potential antiviral drugs on viral gene expression via tdTomato and eGFP expression. In addition, by cloning BKPyV-NCCR amplicons which in this protocol have been exemplarily obtained from the blood-derived DNA of immunocompromised renal transplanted patients, the impact of NCCR-rearrangements on viral gene expression can be determined. Following cloning of the patient derived amplicons, HEK293T cells were transfected with the reporter-plasmids, and treated with potential antiviral agents. Subsequently, cells were subjected to FACS-analysis for measuring mean fluorescence intensities 72 h post transfection. To also test the analysis of drugs that have a potential cell cycle inhibiting effect, only transfected and thus fluorescent cells are used. Since this assay is performed in large T Antigen expressing cells, the impact of early and late expression can be analyzed in a mutually independent manner.

Introduction

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Polyomaviruses represent an independent family of small double-stranded DNA (dsDNA) viruses with the Simian virus 40 (SV40) as a prototype species. The primary infection mainly occurs during the childhood, which usually proceed without disease symptoms and usually cause latent infections in immune competent hosts. The BK-polyomavirus (BKPyV) mainly persists in renal tubules cells without causing nephropathologies, however, in case of impairment of the immune-competence after renal transplantation the virus can reactivate and cause severe damages and impaired graft function when reaching a high viremia (1 x 104 BKPyV DNA copies/mL)1,2. In approximately 10% of kidney transplant recipients, reactivation of the BK-polyomavirus (BKPyV) results in a polyomavirus associated nephropathy (PyVAN), which was up to 80% associated with a high risk of renal allograft failures3,4. Since no approved antiviral agents are available, current therapy is based on the reduction of immunosuppression. Interestingly, mTOR inhibitors seem to have an antiviral effect; thus, switching the immunosuppressive therapy to mTOR-based immunosuppression might represent an alternative approach to prevent progression of the BKPyV viremia5,6,7. However, the mTOR-based antiviral mechanism is currently still incompletely understood. Thus, methods measuring the impact of potential antiviral agents in clinically relevant concentrations are required.

The circular genome of the BKPyV consists of approximately 5 kb harboring a non-coding control region (NCCR) that serves as an origin of replication and concomitantly a bidirectional promoter driving the expression of early and late phase mRNA transcripts. Since spontaneously occurring NCCR-rearrangements, deletions, and duplications are found in pathogenic BKPyV8 and significantly accumulated in patients suffering from PVAN5,9, a comparison of archetypical (wt) and re-arranged (rr) NCCR-activities are helpful to characterize viral replicative fitness.

As summarized in Figure 1, this protocol describes a commonly used method to measure BKPyV NCCR transcriptional activity by quantifying the fluorescence of two fluorophores tdTomato and eGFP expressed from a reporter plasmid5,9,10,11. The procedure is performed in the presence of the SV40 large T antigen (lTAg), which allows to analyze the impact of potential antiviral agents on the early and late NCCR-activity separately5. This assay further analyzes the impact of rearrangements on the NCCR activity and comparison with wt-NCCRs5,9. The reporter plasmid harbors the SV40 late polyadenylation signal downstream of each fluorophore open reading frame to ensure comparable and efficient processing of both transcripts for tdTomato and eGFP, respectively. Compared to qRT-PCR based methods5,12, this FACS-based approach represents a low cost and high throughput compatible alternative since no complicated extraction protocols for infected cell culture and no expensive antibodies for immune fluorescence staining are needed. Furthermore, since a defined amount of fluorescent cells are analyzed via flow cytometry, the analysis of cell cycle inhibiting agents is also possible in a quantitative manner.

Access restricted. Please log in or start a trial to view this content.

Protocol

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

This protocol follows the guidelines of human research as approved by the ethic committee of the medical faculty of the University of Duisburg-Essen (14-6028-BO).

1. Collection of blood or urine samples and isolation of polyomavirus DNA

  1.  Collect at least 3 mL of blood in EDTA tubes or urine in acquisition tubes.
  2. Centrifuge the sample at 2,500 x g for 15 min. If needed, pipette plasma into a new tube and store the plasma samples at 4 °C for several days or freeze at -20 °C for longer storage.
  3. Prepare 40 µL of proteinase K into a 1.5 mL microcentrifuge tube and add 400 µL of plasma by pipetting.
  4. Lyse the sample by adding 400 µL of lysis buffer, vortex for 15 s, and incubate for 10 min at 56 °C.
  5. Isolate the DNA using a DNA blood extraction kit as described in the manufacturer's instructions. Briefly, add alcohol and load the lysates onto a spin column containing a DNA binding silica-based membrane. Wash the columns several times to yield pure DNA.
  6. Elute the yielded DNA in 30-50 µL of TE buffer.

2. Amplification of the non-coding control region (NCCR)

  1. Perform the following procedure in physically separated rooms. Use an isolated room to prepare the reagents and distribute the mix to the PCR tubes.
  2. Prepare the Master Mix for the pre-PCR using primer pair A (Table 1) in a total volume of 50 µL and use the previously isolated DNA from step 1.6. The pipetting scheme for preparing the master mix for the pre and nested PCR is printed in Table 2.
  3. Distribute 45 µL of the master mix into the PCR tubes.
  4. Add 5 µL of the isolated DNA into the PCR tubes.
    NOTE: Use another room than the one for the master mix preparation to avoid contamination.
  5. Run the PCR with the reaction conditions as illustrated in Table 3. Repeat denaturation, annealing, and extension in 35 cycles.
  6. For the nested amplification use primer pair B harboring the restriction sites for AgeI and SpeI (Table 1).
  7. Run the nested PCR with the reaction conditions as described in steps 2.2 to 2.5 using 5 µL of the pre-PCR.
  8. Mix 10 µL of the PCR product with 2 µL of 6x gel loading dye. Load 10 µL of the mix on a 1.5% agarose gel, and run the gel for 30 min at 60 mA.
  9. Visualize the gel using an appropriate UV documentation system.
    NOTE: The size of the amplicon is expected to be between 300-500 bp depending on whether rearrangements (deletions, insertions, or duplications) occurred (Figure 2C).
  10. Purify the PCR amplicons using a PCR purification kit according to the manufacturer's instructions. Elute the PCR amplicons in 30 µL of elution buffer.
  11. Send the amplicons for Sanger sequencing using primer pair B.

3. Cloning of the NCCR into the dual fluorescence reporter

  1. Digest the purified amplicons (step 2.10) with AgeI and SpeI for 2 h at 37 °C as described in Table 4.
  2. Repeat step 2.10 and purify the digested amplicons.
  3. In parallel, also digest the plasmid backbone (1.5 µg) with AgeI and SpeI for 2 h at 37 °C as described in Table 5. This step only needs to be performed once. For subsequent reactions, freeze the digestion at -20 °C.
  4. Analyze the digested plasmid backbone on a 0.8% low melt agarose gel.
    NOTE: Do not run the gel with a current higher than 40 mA. The expected insert of the spacer region originally derived from the plasmid pEX-K4 2-LTR CD313 is 128 bp (Figure 2C).
  5. Visualize DNA fragments using long-wave UV light (320 nm) and cut out the backbone band using a clean scalpel. Transfer the low melt gel fragment into a new 1.5 mL microcentrifuge tube. Avoid long UV exposure times to prevent DNA damage.
    NOTE: Since low melt agarose is used, it is not necessary to purify the DNA before ligation.
  6. Heat the backbone containing the low melt agarose piece for 10 min at 65 °C in order to melt the gel piece and mix every 2 min by gentle vortexing. The melted gel can be directly used for ligation.
  7. Ligate the backbone and the digested amplicon using T4 DNA ligase over night at 16 °C using the scheme shown in Table 6.
  8. Perform transformation in E. coli using the heat shock method, plate bacteria on LB-amp plates, and culture at 37 °C over night.
  9. On the next day, select three positive clones and prepare overnight E. coli cultures (5 mL of LB-Amp) and culture at 37 °C.
  10. Isolate the plasmid-DNA using standard protocols as described elsewhere14, perform AgeI and SpeI digestion to check for positive clones and visualize cut out fragments on a 1% agarose gel. The spacer band (128 bp) will be replaced by the larger NCCR-sequence (300-500 bp, see above).
  11. Send the plasmid for Sanger sequencing using primer EGFP-N or primer pair B (Table 1).
  12. Since mutations might spontaneously occur, compare the sequencing results with the sequencing results obtained with the amplicon. Only use the clones containing identical sequences compared to the amplicon.
  13. Use a molecular workbench software (e.g., freeware GENtle 1.9.4 or other sequence editing programs) to align and edit the obtained sequences (Figure 3).
  14. Start GENtle 1.9.4 and import the DNA sequences by clicking on the Import button (green down arrow).
  15. Next click on Tool and select Alignment from the menu (Use Ctrl+G as a shortcut) and choose the DNA sequences for alignment.
  16. Add a sequence to the alignment by clicking on Add or remove a sequence by clicking on Remove. Include an archetypical NCCR consensus sequence like JN19243815, do not use the NCCR-sequence from the commonly used Dunlop-strain16, since it harbors rearrangements and duplications others than the archetypical BKPyV strains.
    NOTE: The NCCR already contains the translational start codon (Figure 3).
  17. Choose a method for the alignment by clicking on Algorithm in the toolbar and choose clustal W. Set the alignment parameters to match 2; gap extension penalty -1; gap penalty -2 and click on OK to run the alignment.

4. Transient transfection of HEK293T cells with the reporter plasmid and treatment with potential antiviral agents

  1. To prepare sufficient amounts of plasmid DNA for subsequent transfection experiments prepare a 150 mL overnight culture. Isolate the plasmid DNA using a plasmid isolation kit. Alternatively, other plasmid purification kits may be used.
  2. Seed 1 x 105 HEK293T cells in DMEM containing 10% FCS, penicillin and streptomycin (1x) per well of a 12-well plate 24 h prior to transfection and incubate overnight at 37 °C and 5% CO2 to maintain active proliferation during transfection.
    NOTE: Cells should be approximately 80% confluent at transfection.
  3. Place 250 µL of reduced serum media in a sterile tube and add 1 µg of each reporter plasmid DNA and mix gently by pipetting.
  4. Add 3 µL of the transfection reagent to the DNA mixture, mix gently by pipetting and incubate for 15 min. Pre warm the transfection reagent to the ambient temperature of 22 °C and vortex gently before use.
  5. Add the mixture drop-wise to the wells and gently distribute to the well.
  6. After 4 h, replace the supernatant with fresh medium containing the testing agents and solvent control. Incubate at 37 °C until analysis. In this example, the mTOR inhibitors INK128 (100 ng/mL) and rapamycin (100 ng/mL) were used.

5. Fluorescence microscopy and flow cytometry

  1. Check cells for the red and green fluorescence under the fluorescence microscope (Figure 4).
    NOTE: Red and green fluorescence correspond to the early and late BKPyV gene expression, respectively.
  2. After 72 h post transfection, aspirate the supernatant and wash the cells twice with 1 mL of cold PBS.
  3. Gently add 500 µL of trypsin and turn the plate slightly to avoid premature detachment of the cells. This step is important to avoid cell doublets.
  4. After addition, remove the trypsin directly with the same pipette tip.
  5. Incubate the cells for at least 5 min at 37 °C.
  6. Resuspend trypsinized cells with 1 mL of PBS containing 3% FCS and transfer the suspension in pre-labeled FACS tubes.
  7. Add DAPI (1 µg/mL) prior to the FACS analysis.
  8. Analyze the cells using a flow cytometer. For each sample, measure at least 10,000 living cells, which are negative for DAPI staining.

6. Data analysis

  1. Import the data to the flow cytometry analysis software and add samples by Click and Drag into the workspace.
  2. Double click on the imported file and create a graph plot. Choose FSC-A versus SSC-A by clicking on the x- and y-axis. Gate the main cell population by clicking on Polygon at the toolbar and framing the cell population (Figure 5). Name the chosen cell population as required (for example "single cells"). The "single cells" will appear as a new workspace.
  3. Proceed with gating "single cells" for DAPI negative (i.e., "living cells"). To identify living cells compare the cell population with and without DAPI staining. In both plots choose FSC-A versus pacific-blue-A.
  4. Click on the rectangle and choose the DAPI negative cell population, name the chosen cell population "living cells", and create a new dot-plot showing FITC (eGFP) versus PE (tdTomato) as described before.
  5. Add quadrants in "living cells" by choosing Quad from the toolbar. Gate the population by dragging the center of the quadrant to the edge of each population. The quadrants represent 1) eGFP-tdTOM-, 2) eGFP-tdTOM+, 3) eGFP+tdTOM-, 4) eGFP+tdTOM+.
    NOTE: Due to the spectral overlay of emission spectra between FITC and PE, initial compensation is essential to distinguish between red and green signals and to achieve accurate results.
  6. Determine mean fluorescence intensities (MFIs) by right clicking on the quadrant and choosing Add Statistics. Choose Mean and click OK. The mean MFI is now displayed below the population in the section "statistics". Quadrants 2 and 4 correspond to early expression, while quadrants 3 and 4 represent late expression.
  7. Add additional replicates in the same manner for statistical power.
  8. For data interpretation plot MFI values of early and late into a bar plot:
  9. To compare NCCR activities obtained from different donors or virus strains, add an archetypical control or the Dunlop strain16 and set its relative MFIs to 100%, and calculate the relative MFI values. Repeat with each replicate and determine mean and standard deviation.
  10. To evaluate an effect of potential compounds on the transcriptional activity, set the solvent-control to 100% and plot the MFI of the treated cells.

Access restricted. Please log in or start a trial to view this content.

Results

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

In this representative experiment, the BK-polyomavirus Non-Coding Control Region driven transcriptional activity was measured via flow cytometry. In addition, a mTOR inhibitor, which might be used to treat patients after BKPyV reactivation, was tested for its inhibition of the viral early gene expression. To this end, a dual fluorescence-reporter assay was used as published previously5. The overall workflow scheme of the experimental setup is illustrated in

Access restricted. Please log in or start a trial to view this content.

Discussion

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

In this article, a commonly used method is presented that allows for the analysis of the BKPyV non-coding control-region (NCCR) driven early and late promoter activity. The NCCR activity can be measured simultaneously and does not need lysis of the transfected cells. Furthermore, a relatively large number of cells can be analyzed and the co-transfection of additional markers for normalization of the fluorescence values is not necessary.

A critical part of this method is that the cloned NCCR sh...

Access restricted. Please log in or start a trial to view this content.

Disclosures

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Johannes Korth has received grants for speaker's fee and travel expenses from Astellas and Novartis. Marek Widera has received consultancy fees from Novartis. Oliver Witzke has received grants for clinical studies, speaker's fee, honoraria and travel expenses from Amgen, Alexion, Astellas, Basilea, Biotest, Bristol-Myers-Squibb, Correvio, Chiesi, Gilead, Hexal, Janssen, Dr. F. Köhler Chemie, MSD, Novartis, Roche, Pfizer, Sanofi and TEVA.

Acknowledgements

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The authors thank Barbara Bleekmann for excellent technical assistance. These studies were supported by the IFORES-program of the University of Duisburg-Essen Medical School and the RIMUR-program of the University Alliance Ruhr and Mercator Research Center Ruhr (MERCUR). The authors thank the JĂĽrgen-Manchot-Stiftung for the doctoral fellowship of Helene Sertznig and constant support. The collection and use of patient material has been approved by the ethics committee of the medical faculty of the University Duisburg-Essen (14-6028-BO).

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
100 bp ladderNEBN3231Any ladder with a range up to 1 kb can be substituted
2-log ladderNEBN0550Any ladder with a range up to 10 kb can be substituted
Agar-Agar, Kobe ICarl Roth5210.3
AgeI-HFNEBR3552
Ampicillin Natriumsalz CellpureCarl RothHP62.1
Aqua ad iniectabiliaBbraun2351744can be substituted by any manufacturer
BD FACSCanto™ IIBD Biosciences
BD FACSDivaBD Biosciences
DAPISigma10236276001
DFC450C camera moduleLeicaAny camera can be used
DMEMGibco41966-029can be substituted by any manufacturer
DMIL LED microscopeLeicaAny fluorescence microscope can be used
DNA Blood Mini KitQiagen51104can be substituted by any manufacturer
E.coli DH5alpha Competent CellsThermo Scientific18258012
FBS SuperiorMerckMillipore50615Any FBS can be used
FlowJo v10.5.3FlowJo, LLCAny flow cytometry software FBS can be used
Gel Loading Dye, Purple (6X) NEBB7024Any 6x loading dye can be substituted
HEK293T cellsATCC11268These cells constitutively express the simian virus 40 (SV40) large T antigen, and clone 17 was selected specifically for its high transfectability.
HERAcell® 240i CO2 IncubatorThermo Scientificcan be substituted by any manufacturer
HotStar PCR kitQiagen203203
Intas Gel documentation systemIntasAny visualisation system for stained DNA containing agarose gels can be used
Low Melt AgaroseBiozym850081can be substituted by any manufacturer
Opti-MEMInvitrogen31985070can be substituted by any manufacturer
pBKV (34-2)ATCC45025Plasmid harboring the full-length genome of BKPyV strain Dunlop; was used as a positive control; DNA Seq. Acc.: KP412983
PBSGibco14190-136
PCR Cycler MJ Mini 48-Well Personal CyclerBio-Raddiscontinued productAny thermocycler can be used
PCR Nucleotide Mix, 10 mMPromega#C1145can be substituted by any manufacturer
PCR1 and PCR2 Primersmetabionnot applicableDesalted. Dilute to (10 µM) with PCR grade water
PenStrep (100x)Gibco15140-122can be substituted by any manufacturer
Roti®-GelStainCarl Roth3865A fluorescence based stain for measuring dsDNA concentration
SpeI-HFNEBR3133
T4-DNA LigaseNEBM0202
TransIT LT1MirusMIR2300
Trypsin 0.05% - EDTAGibco25300-054can be substituted by any manufacturer
ZymoPURE II Plasmid KitZymoD4201can be substituted by any manufacturer

References

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,
  1. Drachenberg, C. B., et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. American Journal of Transplant. 4 (12), 2082-2092 (2004).
  2. Korth, J., et al. Impact of low-level BK polyomavirus viremia on intermediate-term renal allograft function. Transplant Infectious Disease. 20 (1), (2018).
  3. Hirsch, H. H., et al. European perspective on human polyomavirus infection, replication and disease in solid organ transplantation. Clinical Microbiology and Infection. 20 Suppl 7, 74-88 (2014).
  4. Masutani, K., et al. The Banff 2009 Working Proposal for polyomavirus nephropathy: a critical evaluation of its utility as a determinant of clinical outcome. American Journal of Transplantation. 12 (4), 907-918 (2012).
  5. Korth, J., et al. Impact of immune suppressive agents on the BK-Polyomavirus non coding control region. Antiviral Research. 159, 68-76 (2018).
  6. Hirsch, H. H., Yakhontova, K., Lu, M., Manzetti, J. BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12. Amerian Journal of Transplantation. 16 (3), 821-832 (2016).
  7. Sanchez Fructuoso, A. I., et al. Mammalian target of rapamycin signal inhibitors could play a role in the treatment of BK polyomavirus nephritis in renal allograft recipients. Transplant Infectious Disease. 13 (6), 584-591 (2011).
  8. Moens, U., Johansen, T., Johnsen, J. I., Seternes, O. M., Traavik, T. Noncoding control region of naturally occurring BK virus variants: sequence comparison and functional analysis. Virus Genes. 10 (3), 261-275 (1995).
  9. Gosert, R., et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. Journal of Experimental Medicine. 205 (4), 841-852 (2008).
  10. Bethge, T., et al. Sp1 sites in the noncoding control region of BK polyomavirus are key regulators of bidirectional viral early and late gene expression. Journal of Virology. 89 (6), 3396-3411 (2015).
  11. Gosert, R., Kardas, P., Major, E. O., Hirsch, H. H. Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate. Journal of Virology. 84 (20), 10448-10456 (2010).
  12. Bernhoff, E., Gutteberg, T. J., Sandvik, K., Hirsch, H. H., Rinaldo, C. H. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. American Journal of Transplantation. 8 (7), 1413-1422 (2008).
  13. Widera, M., et al. HIV-1 persistent viremia is frequently followed by episodes of low-level viremia. Medical Microbiology Immunology. , (2017).
  14. Zhang, S., Cahalan, M. D. Purifying plasmid DNA from bacterial colonies using the QIAGEN Miniprep Kit. Journal of Visualized Experiment. (6), 247(2007).
  15. Drew, R. J., Walsh, A., Laoi, B. N., Crowley, B. Phylogenetic analysis of the complete genome of 11 BKV isolates obtained from allogenic stem cell transplant recipients in Ireland. Journal of Medical Virology. 84 (7), 1037-1048 (2012).
  16. Dorries, K., Vogel, E., Gunther, S., Czub, S. Infection of human polyomaviruses JC and BK in peripheral blood leukocytes from immunocompetent individuals. Virology. 198 (1), 59-70 (1994).
  17. Teutsch, K., et al. Early identification of renal transplant recipients with high risk of polyomavirus-associated nephropathy. Medical Microbiology Immunology. 204 (6), 657-664 (2015).
  18. Basu, S., Campbell, H. M., Dittel, B. N., Ray, A. Purification of specific cell population by fluorescence activated cell sorting (FACS). Journal of Visualized Experiment. (41), (2010).
  19. Korth, J., et al. The detection of BKPyV genotypes II and IV after renal transplantation as a simple tool for risk assessment for PyVAN and transplant outcome already at early stages of BKPyV reactivation. Journal of Clinical Virology. 113, 14-19 (2019).
  20. Caputo, A., Barbanti-Brodano, G., Wang, E., Ricciardi, R. P. Transactivation of BKV and SV40 early promoters by BKV and SV40 T-antigens. Virology. 152 (2), 459-465 (1986).
  21. Shaner, N. C., Steinbach, P. A., Tsien, R. Y. A guide to choosing fluorescent proteins. Nature Methods. 2 (12), 905-909 (2005).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

BK PolyomavirusNon Coding Control RegionTranscriptional ActivityFlow CytometryDual Fluorescence ReporterHEK293T CellsAntiviral AgentsNCCR RearrangementsEarly Late Gene ExpressionFluorescence Microscopy

Related Articles